Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6607121 | 0.92 | CYP17A1 (0.58) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL13055402 | 0.88 | CYP17A1 (0.59) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL23619661 | 0.82 | SMN1; SMN2 (0.62) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL20865536 | 0.82 | CYP17A1 (0.68) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL775002 | 0.82 | NAMPT (0.56) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL1196294 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2 | |
| SCHEMBL693943 | 0.82 | CYP17A1 (0.59) | CYP17A1 | |
| Water SCHEMBL27835379 | 0.81 | PSMB8 (0.52) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL359513 | 0.81 | NAMPT (0.46) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL1455948 | 0.81 | CYP17A1 (0.54) | CYP17A1PSMB8NAMPTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 342 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924160-A | Pyridine fluorescent probe for in-vitro rapid detection of gamma-glutamyl transpeptidase and preparation method and application thereof | 赣南医学院 | 2024-04-26 | — | — | CN | claimed |
| CN-117396477-A | Pyridyl-substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-01-12 | — | — | CN | claimed |
| CN-113461636-B | Benzothiazole-containing phenylalanine derivative and preparation method and application thereof | 山东大学 | 2023-08-08 | — | — | CN | claimed |
| CN-116462671-A | N- (tert-butyl) -2- (N-acetamido) formamide compound and preparation method and application thereof | 陕西盘龙药业集团股份有限公司 | 2023-07-21 | — | — | CN | claimed |
| CN-115611781-A | Novel method for preparing alkyl sulfonamide from fatty amine sulfonyl chloride | 天津师范大学 | 2023-01-17 | — | — | CN | claimed |
| EP-3218374-B1 | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2021-12-29 | — | — | EP | claimed |
| CN-113461636-A | Benzothiazole-containing phenylalanine derivative and preparation method and application thereof | 山东大学 | 2021-10-01 | — | — | CN | claimed |
| CN-107108614-B | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2021-06-01 | — | — | CN | claimed |
| EP-3241829-B1 | HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2020-12-23 | — | — | EP | claimed |
| US-10150767-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2018-12-11 | — | — | US | claimed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | claimed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| WO-2008094602-A2 | 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | claimed |
| CN-101137630-A | Non-anilinic derivatives of isothiazol-3(2h)-thione 1,1-dioxides as liver x receptor modulators | ASTRAZENECA AB (SE) | 2008-03-05 | — | — | CN | claimed |
| EP-1838686-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | claimed |
| WO-2006073363-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | claimed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | claimed |
| EP-1309589-A2 | UREA COMPOUNDS AND METHODS OF USES | Amgen Inc. (US) | 2003-05-14 | — | — | EP | claimed |
| US-20020173507-A1 | Urea compounds and methods of uses | AMGEN INC. | 2002-11-21 | — | — | US | claimed |
| WO-2002014311-A2 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC. (US) | 2002-02-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173507-A1 | Urea compounds and methods of uses | SLC14A1, UMPS, BAX | CYP17A1 2641/4885PSMB8 3054/4885NAMPT 365/4885 |
| US-10150767-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | CYP17A1 1268/4885PSMB8 2678/4885NAMPT 549/4885 |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | CYP17A1 102/4885PSMB8 2680/4885NAMPT 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.